FMP
Jan 20, 2026
Truist Financial Corporation, listed as NYSE:TFC, is a prominent player in the financial services sector. The company is set to release its quarterly earnings on January 21, 2026. Analysts expect earnings per share (EPS) to be $1.09, with projected revenue of approximately $5.32 billion. These figures are crucial as they can influence TFC's stock price.
TFC is anticipated to report a 19.8% increase in EPS compared to the same period last year, as highlighted by Zacks. This growth is driven by a 4.1% year-over-year revenue increase, with analysts forecasting revenues of $5.27 billion. The consensus EPS estimate has been revised upward by 0.7% over the past 30 days, indicating positive sentiment among analysts.
Despite challenges from Federal Reserve rate cuts, TFC's net interest income (NII) is expected to rise by 3.2%. This increase is attributed to strong loan demand and reduced deposit costs. Non-interest income is also projected to grow by 6.5%, supported by stronger fee income across various segments. These factors contribute to the anticipated 1-2% sequential growth in adjusted fourth-quarter revenues.
TFC's loan portfolio shows promising trends, with commercial and industrial loans making up nearly half of total loans and leases. Consumer loan demand, accounting for about 40% of total loans, remains solid. The Zacks Consensus Estimate for TFC's average earning assets is set at $490.4 billion, reflecting a 3.7% increase, further supporting the company's growth prospects.
TFC's financial metrics provide insight into its market valuation. The company has a price-to-earnings (P/E) ratio of approximately 12.29 and a price-to-sales ratio of about 2.11. The enterprise value to sales ratio is around 3.23, while the enterprise value to operating cash flow ratio is approximately 25.01. Despite a debt-to-equity ratio of about 1.08, the current ratio is low at approximately 0.13, suggesting potential liquidity concerns.
Ondas Inc. (NASDAQ:ONDS) is a company that specializes in developing advanced wireless data and drone solutions. It oper...
Rapt Therapeutics, trading on the NASDAQ under the symbol RAPT, is a clinical-stage biopharmaceutical company based in C...